Skip to main content

Advertisement

SpringerLink
Log in

Tau-induced neurodegeneration: mechanisms and targets

  • Review
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

The accumulation of hyperphosphorylated tau is a common feature of several dementias. Tau is one of the brain microtubule-associated proteins. Here we discuss tau’s functions in microtubule assembly and stabilization and with regard to its interactions with other proteins. We describe and analyze important post-translational modifications: hyperphosphorylation, ubiquitination, glycation, glycosylation, nitration, polyamination, proteolysis, acetylation, and methylation. We discuss how these post-translational modifications can alter tau’s biological function. We analyze the role of mitochondrial health in neurodegeneration. We propose that microtubules could be a therapeutic target and review different approaches. Finally, we consider whether tau accumulation or its conformational change is related to tau-induced neurodegeneration, and propose a mechanism of neurodegeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging 1998, 19: 173–189.

    PubMed  CAS  Google Scholar 

  2. Saxena U. Bioenergetics breakdown in Alzheimer’s disease: targets for new therapies. Int J Physiol Pathophysiol Pharmacol 2011, 3: 133–139.

    PubMed Central  PubMed  CAS  Google Scholar 

  3. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120: 885–890.

    PubMed  CAS  Google Scholar 

  4. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986, 261: 6084–6089.

    PubMed  CAS  Google Scholar 

  5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986, 83: 4913–4917.

    PubMed Central  PubMed  CAS  Google Scholar 

  6. Tharp WG, Sarkar IN. Origins of amyloid-beta. BMC Genomics 2013, 14: 290.

    PubMed Central  PubMed  CAS  Google Scholar 

  7. Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003, 70: 1–32.

    PubMed  CAS  Google Scholar 

  8. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990, 87: 257–263.

    PubMed  CAS  Google Scholar 

  9. Lamb BT, Sisodia SS, Lawler AM, Slunt HH, Kitt CA, Kearns WG, et al. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat Genet 1993, 5: 22–30.

    PubMed  CAS  Google Scholar 

  10. Morais VA, De Strooper B. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. J Alzheimers Dis 2010, 20 Suppl 2: S255–263.

    Google Scholar 

  11. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997, 20: 154–159.

    PubMed  CAS  Google Scholar 

  12. Alonso AC, Li B, Grundke-Iqbal I, Iqbal K. Mechanism of tauinduced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2008, 5: 375–384.

    PubMed  CAS  Google Scholar 

  13. Goux WJ, Rodriguez S, Sparkman DR. Characterization of the glycolipid associated with Alzheimer paired helical filaments. J Neurochem 1996, 67: 723–733.

    PubMed  CAS  Google Scholar 

  14. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975, 72: 1858–1862.

    PubMed Central  PubMed  CAS  Google Scholar 

  15. Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer’s disease. J Alzheimers Dis 2006, 9: 195–207.

    PubMed  CAS  Google Scholar 

  16. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubuleassociated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 1986, 387: 271–280.

    PubMed  CAS  Google Scholar 

  17. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007, 8: 663–672.

    PubMed  CAS  Google Scholar 

  18. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24: 1121–1159.

    PubMed  CAS  Google Scholar 

  19. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013, 9: 1–11 e13.

    PubMed  Google Scholar 

  20. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118: 53–69.

    PubMed Central  PubMed  CAS  Google Scholar 

  21. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009, 68: 709–735.

    PubMed Central  PubMed  Google Scholar 

  22. Small GW, Kepe V, Siddarth P, Ercoli LM, Merrill DA, Donoghue N, et al. PET scanning of brain tau in retired national football league players: preliminary findings. Am J Geriatr Psychiatry 2013, 21: 138–144.

    PubMed  Google Scholar 

  23. Buee L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, et al. From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans 2010, 38: 967–972.

    PubMed  CAS  Google Scholar 

  24. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005, 1739: 280–297.

    PubMed  CAS  Google Scholar 

  25. Corbo CP, Alonso Adel C. Therapeutic targets in Alzheimer’s disease and related tauopathies. Prog Mol Biol Transl Sci 2011, 98: 47–83.

    PubMed  CAS  Google Scholar 

  26. Brion JP, Smith C, Couck AM, Gallo JM, Anderton BH. Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer’s disease. J Neurochem 1993, 61: 2071–2080.

    PubMed  CAS  Google Scholar 

  27. Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O’Connor M, Trojanowski JQ, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron 1994, 13: 989–1002.

    PubMed  CAS  Google Scholar 

  28. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 2013, 33 Suppl 1: S123–139.

    Google Scholar 

  29. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 2001, 98: 6923–6928.

    PubMed Central  PubMed  CAS  Google Scholar 

  30. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A 1994, 91: 5562–5566.

    PubMed Central  PubMed  CAS  Google Scholar 

  31. Hanger DP, Noble W. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011, 2011: 352805.

    PubMed Central  PubMed  Google Scholar 

  32. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J 1990, 9: 2431–2438.

    PubMed Central  PubMed  CAS  Google Scholar 

  33. Utton MA, Vandecandelaere A, Wagner U, Reynolds CH, Gibb GM, Miller CC, et al. Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule selfassembly. Biochem J 1997, 323(Pt 3): 741–747.

    PubMed Central  PubMed  CAS  Google Scholar 

  34. Li G, Yin H, Kuret J. Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem 2004, 279: 15938–15945.

    PubMed  CAS  Google Scholar 

  35. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, et al. Activation of glycogen synthase kinase-3 inhibits longterm potentiation with synapse-associated impairments. J Neurosci 2007, 27: 12211–12220.

    PubMed  CAS  Google Scholar 

  36. Zhu LQ, Liu D, Hu J, Cheng J, Wang SH, Wang Q, et al. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J Neurosci 2010, 30: 3624–3633.

    PubMed  CAS  Google Scholar 

  37. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012, 33: 1400–1410.

    PubMed  Google Scholar 

  38. Peng CX, Hu J, Liu D, Hong XP, Wu YY, Zhu LQ, et al. Disease-modified glycogen synthase kinase-3beta intervention by melatonin arrests the pathology and memory deficits in an Alzheimer’s animal model. Neurobiol Aging 2013, 34: 1555–1563.

    PubMed  CAS  Google Scholar 

  39. Smith DS, Tsai LH. Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol 2002, 12: 28–36.

    PubMed  Google Scholar 

  40. Hamdane M, Sambo AV, Delobel P, Begard S, Violleau A, Delacourte A, et al. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem 2003, 278: 34026–34034.

    PubMed  CAS  Google Scholar 

  41. Marx A, Nugoor C, Panneerselvam S, Mandelkow E. Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases. FASEB J 2010, 24: 1637–1648.

    PubMed  CAS  Google Scholar 

  42. Timm T, Marx A, Panneerselvam S, Mandelkow E, Mandelkow EM. Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC Neurosci 2008, 9 Suppl 2: S9.

    Google Scholar 

  43. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004, 116: 671–682.

    PubMed  CAS  Google Scholar 

  44. Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet 2009, 18: 164–177.

    PubMed Central  PubMed  CAS  Google Scholar 

  45. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000, 33: 95–130.

    PubMed  CAS  Google Scholar 

  46. Tian Q, Wang J. Role of serine/threonine protein phosphatase in Alzheimer’s disease. Neurosignals 2002, 11: 262–269.

    PubMed  CAS  Google Scholar 

  47. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci U S A 2004, 101: 10804–10809.

    PubMed Central  PubMed  CAS  Google Scholar 

  48. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubulebinding activity of Tau by protein phosphatase 2A. Neuron 1996, 17: 1201–1207.

    PubMed  CAS  Google Scholar 

  49. Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 1999, 274: 25490–25498.

    PubMed  CAS  Google Scholar 

  50. Liu GP, Zhang Y, Yao XQ, Zhang CE, Fang J, Wang Q, et al. Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms. Neurobiol Aging 2008, 29: 1348–1358.

    PubMed  CAS  Google Scholar 

  51. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 2010, 19: 1221–1229.

    PubMed  CAS  Google Scholar 

  52. Sun XY, Wei YP, Xiong Y, Wang XC, Xie AJ, Wang XL, et al. Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2A (PP2A). J Biol Chem 2012, 287: 11174–11182.

    PubMed Central  PubMed  CAS  Google Scholar 

  53. Xiong Y, Jing XP, Zhou XW, Wang XL, Yang Y, Sun XY, et al. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging 2013, 34: 745–756.

    PubMed  CAS  Google Scholar 

  54. Nayeem N, Kerr F, Naumann H, Linehan J, Lovestone S, Brandner S. Hyperphosphorylation of tau and neurofilaments and activation of CDK5 and ERK1/2 in PTEN-deficient cerebella. Mol Cell Neurosci 2007, 34: 400–408.

    PubMed  CAS  Google Scholar 

  55. Tremblay MA, Acker CM, Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer’s disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis 2010, 19: 721–733.

    PubMed Central  PubMed  CAS  Google Scholar 

  56. Bhaskar K, Hobbs GA, Yen SH, Lee G. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol Appl Neurobiol 2010, 36: 462–477.

    PubMed Central  PubMed  CAS  Google Scholar 

  57. Ho GJ, Hashimoto M, Adame A, Izu M, Alford MF, Thal LJ, et al. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer’s disease: implications for its functional role. Neurobiol Aging 2005, 26: 625–635.

    PubMed  CAS  Google Scholar 

  58. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011, 2: 252.

    PubMed Central  PubMed  Google Scholar 

  59. Riederer BM, Leuba G, Elhajj Z. Oxidation and ubiquitination in neurodegeneration. Exp Biol Med (Maywood) 2013, 238: 519–524.

    Google Scholar 

  60. Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 2012, 317: 1–5.

    PubMed  CAS  Google Scholar 

  61. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer’s disease. Nat Med 1996, 2: 871–875.

    PubMed  CAS  Google Scholar 

  62. Reyes JF, Fu Y, Vana L, Kanaan NM, Binder LI. Tyrosine nitration within the proline-rich region of Tau in Alzheimer’s disease. Am J Pathol 2011, 178: 2275–2285.

    PubMed Central  PubMed  CAS  Google Scholar 

  63. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochem Int 2011, 58: 458–471.

    PubMed  CAS  Google Scholar 

  64. Chesser AS, Pritchard SM, Johnson GV. Tau Clearance Mechanisms and Their Possible Role in the Pathogenesis of Alzheimer Disease. Front Neurol 2013, 4: 122.

    PubMed Central  PubMed  Google Scholar 

  65. Thomas SN, Funk KE, Wan Y, Liao Z, Davies P, Kuret J, et al. Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol 2012, 123: 105–117.

    PubMed Central  PubMed  CAS  Google Scholar 

  66. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67: 953–966.

    PubMed Central  PubMed  CAS  Google Scholar 

  67. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, et al. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet 2012, 21: 2936–2945.

    PubMed Central  PubMed  CAS  Google Scholar 

  68. Zhang L, Sheng S, Qin C. The role of HDAC6 in Alzheimer’s disease. J Alzheimers Dis 2013, 33: 283–295.

    PubMed  Google Scholar 

  69. Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 2014, 23: 104–116.

    PubMed Central  PubMed  CAS  Google Scholar 

  70. Choi H, Fermin D, Nesvizhskii AI. Significance analysis of spectral count data in label-free shotgun proteomics. Mol Cell Proteomics 2008, 7: 2373–2385.

    PubMed Central  PubMed  CAS  Google Scholar 

  71. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease. J Neurochem 2009, 111: 242–249.

    PubMed Central  PubMed  CAS  Google Scholar 

  72. Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 2012, 8: 393–399.

    PubMed  CAS  Google Scholar 

  73. Iqbal K, Gong CX, Liu F. Hyperphosphorylation-induced tau oligomers. Front Neurol 2013, 4: 112.

    PubMed Central  PubMed  Google Scholar 

  74. Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P. SUMO and Alzheimer’s disease. Neuromolecular Med 2013, 15: 720–736.

    PubMed  CAS  Google Scholar 

  75. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994, 91: 4766–4770.

    PubMed Central  PubMed  CAS  Google Scholar 

  76. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996, 383: 550–553.

    PubMed  CAS  Google Scholar 

  77. Chen H, Chan DC. Critical dependence of neurons on mitochondrial dynamics. Curr Opin Cell Biol 2006, 18: 453–459.

    PubMed  CAS  Google Scholar 

  78. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci 2009, 29: 9090–9103.

    PubMed Central  PubMed  CAS  Google Scholar 

  79. Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 2010, 1802: 135–142.

    PubMed Central  PubMed  CAS  Google Scholar 

  80. Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson’s disease. Biochim Biophys Acta 2010, 1802: 29–44.

    PubMed  CAS  Google Scholar 

  81. Shi P, Wei Y, Zhang J, Gal J, Zhu H. Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. J Alzheimers Dis 2010, 20 Suppl 2: S311–324.

    Google Scholar 

  82. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, et al. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease. J Alzheimers Dis 2010, 20Suppl 2: S401–412.

    PubMed Central  PubMed  Google Scholar 

  83. Manczak M, Reddy PH. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 2012, 21: 2538–2547.

    PubMed Central  PubMed  CAS  Google Scholar 

  84. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res 2011, 1415: 136–148.

    PubMed Central  PubMed  CAS  Google Scholar 

  85. Silva DF, Esteves AR, Oliveira CR, Cardoso SM. Mitochondria: the common upstream driver of amyloid-beta and tau pathology in Alzheimer’s disease. Curr Alzheimer Res 2011, 8: 563–572.

    PubMed  CAS  Google Scholar 

  86. Chan DC. Mitochondrial dynamics in disease. N Engl J Med 2007, 356: 1707–1709.

    PubMed  CAS  Google Scholar 

  87. Chen H, Chan DC. Mitochondrial dynamics in mammals. Curr Top Dev Biol 2004, 59: 119–144.

    PubMed  CAS  Google Scholar 

  88. Verstreken P, Ly CV, Venken KJ, Koh TW, Zhou Y, Bellen HJ. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 2005, 47: 365–378.

    PubMed  CAS  Google Scholar 

  89. Smirnova E, Griparic L, Shurland DL, van der Bliek AM. Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 2001, 12: 2245–2256.

    PubMed Central  PubMed  CAS  Google Scholar 

  90. Yoon Y, Krueger EW, Oswald BJ, McNiven MA. The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1. Mol Cell Biol 2003, 23: 5409–5420.

    PubMed Central  PubMed  CAS  Google Scholar 

  91. Yonashiro R, Ishido S, Kyo S, Fukuda T, Goto E, Matsuki Y, et al. A novel mitochondrial ubiquitin ligase plays a critical role in mitochondrial dynamics. Embo J 2006, 25: 3618–3626.

    PubMed Central  PubMed  CAS  Google Scholar 

  92. Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S. MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology. EMBO Rep 2006, 7: 1019–1022.

    PubMed Central  PubMed  CAS  Google Scholar 

  93. Karbowski M, Neutzner A, Youle RJ. The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J Cell Biol 2007, 178: 71–84.

    PubMed Central  PubMed  CAS  Google Scholar 

  94. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci 2001, 114: 867–874.

    PubMed  CAS  Google Scholar 

  95. Ishihara N, Eura Y, Mihara K. Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J Cell Sci 2004, 117: 6535–6546.

    PubMed  CAS  Google Scholar 

  96. Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A 2004, 101: 15927–15932.

    PubMed Central  PubMed  CAS  Google Scholar 

  97. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004, 36: 449–451.

    PubMed  Google Scholar 

  98. Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem 2003, 278: 7743–7746.

    PubMed  CAS  Google Scholar 

  99. Duboff B, Gotz J, Feany MB. Tau Promotes Neurodegeneration via DRP1 Mislocalization In Vivo. Neuron 2012, 75: 618–632.

    PubMed Central  PubMed  CAS  Google Scholar 

  100. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, et al. Alzheimer’s disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol 2010, 3: 570–581.

    PubMed Central  PubMed  CAS  Google Scholar 

  101. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 2010, 285: 30851–30860.

    PubMed Central  PubMed  CAS  Google Scholar 

  102. Whiteman IT, Minamide LS, Goh de L, Bamburg JR, Goldsbury C. Rapid changes in phospho-MAP/tau epitopes during neuronal stress: cofilin-actin rods primarily recruit microtubule binding domain epitopes. PLoS One 2011, 6: e20878.

    PubMed Central  PubMed  CAS  Google Scholar 

  103. Goldbaum O, Richter-Landsberg C. Proteolytic stress causes heat shock protein induction, tau ubiquitination, and the recruitment of ubiquitin to tau-positive aggregates in oligodendrocytes in culture. J Neurosci 2004, 24: 5748–5757.

    PubMed  CAS  Google Scholar 

  104. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, et al. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain. Am J Pathol 2011, 179: 2071–2082.

    PubMed Central  PubMed  CAS  Google Scholar 

  105. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci U S A 2009, 106: 20057–20062.

    PubMed Central  PubMed  CAS  Google Scholar 

  106. Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 2007, 27: 2896–2907.

    PubMed  CAS  Google Scholar 

  107. Guo X, Macleod GT, Wellington A, Hu F, Panchumarthi S, Schoenfield M, et al. The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. Neuron 2005, 47: 379–393.

    PubMed  CAS  Google Scholar 

  108. Stowers RS, Megeath LJ, Gorska-Andrzejak J, Meinertzhagen IA, Schwarz TL. Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein. Neuron 2002, 36: 1063–1077.

    PubMed  CAS  Google Scholar 

  109. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002, 156: 1051–1063.

    PubMed Central  PubMed  CAS  Google Scholar 

  110. Shahpasand K, Uemura I, Saito T, Asano T, Hata K, Shibata K, et al. Regulation of mitochondrial transport and intermicrotubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer’s disease. J Neurosci 2012, 32: 2430–2441.

    PubMed  CAS  Google Scholar 

  111. Iijima-Ando K, Sekiya M, Maruko-Otake A, Ohtake Y, Suzuki E, Lu B, et al. Loss of axonal mitochondria promotes taumediated neurodegeneration and Alzheimer’s disease-related tau phosphorylation via PAR-1. PLOS Genetics 2013, 8: e1002918.

    Google Scholar 

  112. Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ. Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease. Future Med Chem 2012, 4: 1751–1761.

    PubMed Central  PubMed  CAS  Google Scholar 

  113. Pogacic Kramp V. List of drugs in development for neurodegenerative diseases: update October 2011. Neurodegener Dis 2012, 9: 210–283.

    PubMed  Google Scholar 

  114. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22: 7280–7295.

    PubMed  CAS  Google Scholar 

  115. Amos LA, Lowe J. How Taxol stabilises microtubule structure. Chem Biol 1999, 6: R65–69.

    PubMed  CAS  Google Scholar 

  116. Alonso Adel C, Corbo CP. Novel therapeutics based on tau/microtubule dynamics: WO2008084483. Expert Opin Ther Pat 2009, 19: 1335–1338.

    PubMed  Google Scholar 

  117. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007, 4: 507–509.

    PubMed  CAS  Google Scholar 

  118. Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson’s disease. Biochim Biophys Acta 2014, 1842: 7–21.

    PubMed  CAS  Google Scholar 

  119. Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis 2013, 56: 79–94.

    PubMed  CAS  Google Scholar 

  120. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010, 40: 385–403.

    PubMed  CAS  Google Scholar 

  121. Shytle RD, Tan J, Bickford PC, Rezai-Zadeh K, Hou L, Zeng J, et al. Optimized turmeric extract reduces beta-Amyloid and phosphorylated Tau protein burden in Alzheimer’s transgenic mice. Curr Alzheimer Res 2012, 9: 500–506.

    PubMed  CAS  Google Scholar 

  122. Dolai S, Shi W, Corbo C, Sun C, Averick S, Obeysekera D, et al. “Clicked” sugar-curcumin conjugate: modulator of amyloidbeta and tau peptide aggregation at ultralow concentrations. ACS Chem Neurosci 2011, 2: 694–699.

    PubMed Central  PubMed  CAS  Google Scholar 

  123. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008, 1214: 177–187.

    PubMed  CAS  Google Scholar 

  124. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996, 2: 783–787.

    PubMed  CAS  Google Scholar 

  125. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A 1997, 94: 298–303.

    PubMed Central  PubMed  CAS  Google Scholar 

  126. Beharry C, Alaniz ME, Alonso Adel C. Expression of Alzheimer-like pathological human tau induces a behavioral motor and olfactory learning deficit in Drosophila melanogaster. J Alzheimers Dis 2013, 37: 539–550.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology and Center for Developmental Neuroscience, College of Staten Island, Graduate Center, The City University of New York, Staten Island, NY, 10314, USA

    Cindy Beharry, Leah S. Cohen, Jing Di, Kawsar Ibrahim, Susan Briffa-Mirabella & Alejandra del C. Alonso

Authors
  1. Cindy Beharry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leah S. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Di
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kawsar Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan Briffa-Mirabella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alejandra del C. Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alejandra del C. Alonso.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beharry, C., Cohen, L.S., Di, J. et al. Tau-induced neurodegeneration: mechanisms and targets. Neurosci. Bull. 30, 346–358 (2014). https://doi.org/10.1007/s12264-013-1414-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-013-1414-z

Keywords

Search

Navigation